Mesenteric Adipocyte Dysfunction in Crohn's Disease is Associated with Hypoxia

Inflammatory Bowel Diseases

Volumn 22, Issue 1, 2016, Pages 114-126

  Zuo, Lugen ^a   Li, Yi ^a   Zhu, Weiming ^a   Shen, Bo ^b   Gong, Jianfeng ^a   Guo, Zhen ^a   Zhang, Wei ^a   Wu, Rong ^a   Gu, Lili ^a   Li, Ning ^a   Li, Jieshou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Crohn's disease; dysfunction; hypoxia; mesenteric adipose tissue

Indexed keywords

ALDOLASE C; COLLAGEN; FATTY ACID SYNTHASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTIC ACID; LIPID; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE;

ADULT; ARTICLE; CELL HYPOXIA; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; HUMAN TISSUE; ILEUM; INFLAMMATION; INTESTINE RESECTION; INTESTINE WALL; LIPID STORAGE; MALE; MESENTERIC FAT; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ADIPOCYTE; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW UP; GENETICS; HYPOXIA; MESENTERY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADIPOCYTES; ADULT; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CROHN DISEASE; CYTOKINES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; HYPOXIA; IMMUNOENZYME TECHNIQUES; MALE; MESENTERY; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84964663760     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000571     Document Type: Article

References (45)

1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: A pathologic and clinical entity. 1932. Mt Sinai J Med. 2000;67:263-268.
2. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al. Mesenteric fat in Crohn's disease: A pathogenetic hallmark or an innocent bystander. Gut. 2007;56:577-583.
3. Kredel LI, Batra A, Stroh T, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn's disease. Gut. 2013;62:852-862.
4. Yamamoto K, Kiyohara T, Murayama Y, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut. 2005;54:789-796.
5. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology. 1999; 117:73-81.
6. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut. 2012;61:78-85.
7. Li Y, Zhu W, Gong J, et al. Influence of exclusive enteral nutrition therapy on visceral fat in patients with Crohn's disease. Inflamm Bowel Dis. 2014; 20:1568-1574.
8. Erhayiem B, Dhingsa R, Hawkey CJ, et al. Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:684-687.e1.
9. Katznelson L, Fairfield WP, Zeizafoun N, et al. Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab. 2003;88:5468-5472.
10. Shamir R. Nutritional aspects in inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48(suppl 2):S86-S88.
11. Benjamin J, Makharia GK, Kalaivani M, et al. Nutritional status of patients with Crohn's disease. Indian J Gastroenterol. 2008;27:195-200.
12. Ghoshal UC, Shukla A. Malnutrition in inflammatory bowel disease patients in northern India: frequency and factors influencing its development. Trop Gastroenterol. 2008;29:95-97.
13. Molica F, Morel S, Kwak BR, et al. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost. 2014;113:553-566.
14. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85-97.
15. Olivier I, Theodorou V, Valet P, et al. Is Crohn's creeping fat an adipose tissue. Inflamm Bowel Dis. 2011;17:747-757.
16. Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955-958.
17. Theiss AL, Fuller CR, Simmons JG, et al. Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation. Gastroenterology. 2005;129:204-219.
18. Feng Y, Li Y, Mei S, et al. Exclusive enteral nutrition ameliorates mesenteric adipose tissue alterations in patients with active Crohn's disease. Clin Nutr. 2014;33:850-858.
19. Wu LL, Chiu HD, Peng WH, et al. Epithelial inducible nitric oxide synthase causes bacterial translocation by impairment of enterocytic tight junctions via intracellular signals of Rho-associated kinase and protein kinase C zeta. Crit Care Med. 2011;39:2087-2098.
20. Dong W, Zhang Z, Liu Z, et al. Protective effects of osthole, a natural derivative of coumarin, against intestinal ischemia-reperfusion injury in mice. Int J Mol Med. 2013;31:1367-1374.
21. Stenman LK, Holma R, Eggert A, et al. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. Am J Physiol Gastrointest Liver Physiol. 2013;304:G227-G234.
22. Ke SZ, Ni XY, Zhang YH, et al. Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-kappaB pathway in lung cancer cells. Int J Oncol. 2013;42:1289-1296.
23. Di PNC, Tuve S, Ni S, et al. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res. 2006;66:960-969.
24. Cheng YT, Wu SL, Ho CY, et al. Beneficial effects of Camellia oil (Camellia oleifera Abel.) on ketoprofen-induced gastrointestinal mucosal damage through upregulation of HO-1 and VEGF. J Agric Food Chem. 2014;62:642-650.
25. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46:2347-2355.
26. Upton JW, Chan FK. Staying alive: cell death in antiviral immunity. Mol Cell. 2014;54:273-280.
27. Kenneth NS, Rocha S. Regulation of gene expression by hypoxia. Biochem J. 2008;414:19-29.
28. Wang B, Wood IS, Trayhurn P. PCR arrays identify metallothionein-3 as a highly hypoxia-inducible gene in human adipocytes. Biochem Biophys Res Commun. 2008;368:88-93.
29. Ambalavanan N, Nicola T, Hagood J, et al. Transforming growth factorbeta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung. Am J Physiol Lung Cell Mol Physiol. 2008;295:L86-L95.
30. Wrana JL, Attisano L. The Smad pathway. Cytokine Growth Factor Rev. 2000;11:5-13.
31. Seystahl K, Tritschler I, Szabo E, et al. Differential regulation of TGFbeta-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma.LID-nou218 [pii]. Neuro Oncol. 2015;17:254-265.
32. He ZW, Qin YH, Wang ZW, et al. HMGB1 acts in synergy with lipopolysaccharide in activating rheumatoid synovial fibroblasts via p38 MAPK and NF-kappaB signaling pathways. Mediators Inflamm. 2013; 2013:596716.
33. Zoico E, Garbin U, Olioso D, et al. The effects of adiponectin on interleukin-6 and MCP-1 secretion in lipopolysaccharide-treated 3T3-L1 adipocytes: role of the NF-kappaB pathway. Int J Mol Med. 2009;24:847-851.
34. Spencer M, Unal R, Zhu B, et al. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab. 2011;96:E1990-E1998.
35. Virtanen KA, Lonnroth P, Parkkola R, et al. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J Clin Endocrinol Metab. 2002;87: 3902-3910.
36. Jansson PA, Larsson A, Lonnroth PN. Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without noninsulin-dependent diabetes mellitus. Eur J Clin Invest. 1998;28:813-818.
37. Wang CY, Guttridge DC, Mayo MW, et al. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999;19:5923-5929.
38. Chai X, Kong W, Liu L, et al. A viral vector expressing hypoxia-inducible factor 1 alpha inhibits hippocampal neuronal apoptosis. Neural Regen Res. 2014;9:1145-1153.
39. Yang B, He K, Zheng F, et al. Over-expression of hypoxia-inducible factor-1 alpha in vitro protects the cardiac fibroblasts from hypoxiainduced apoptosis. J Cardiovasc Med (Hagerstown). 2014;15:579-586.
40. Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch. 2005;450:363-371.
41. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol. 2008;121:326-330.
42. Schaffler A, Herfarth H. Creeping fat in Crohn's disease: travelling in a creeper lane of research. Gut. 2005;54:742-744.
43. Goncalves P, Magro F, Martel F. Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel. Inflamm Bowel Dis. 2015;21:453-467.
44. Bertin B, Desreumaux P, Dubuquoy L. Obesity, visceral fat and Crohn's disease. Curr Opin Clin Nutr Metab Care. 2010;13:574-580.
45. Li Y, Zhu W, Gong J, et al. Visceral fat area is associated with a high Risk for early postoperative recurrence in Crohn's disease. Colorectal Dis. 2015;17:225-234.